Celgene (CELG) told investors last week that its experimental CAR-T therapy for patients with the blood cancer multiple myeloma would be submitted to regulators in the first half of 2020. Naturally, that filing presupposes a positive outcome from an ongoing Phase 3 clinical trial. So when will those data be disclosed?
On that not-so-minor question, Celgene remains noncommittal, except to say the results on the treatment called bb2121 will be known later this year. Meanwhile, Celgene’s partner, Bluebird Bio (BLUE), is also withholding long-term patient outcomes from an earlier clinical trial of bb2121. That decision hasn’t attracted as much scrutiny as it deserves.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
The BMY deal to buy CELG might be cause to hold data.